ADIPOQ and metabolic syndrome: In contrast, treatment with Ang II blockers increased plasma adiponectin levels in both in humans and animals with metabolic syndrome or diabetes (Kurata et al. 2006; Fuke et al. 2010; Tian et al. 2010; Rinaldi et al. 2012).